Highly bioavailable curcumin in COVID-19 with no symptoms.

A double-blind, randomized placebo-controlled study evaluating the effect of highly bioavailable curcumin on prevention of disesase progression in coronavirus disease 2019 (COVID-19) patients with no symptoms. - Curcu-COVID study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051210176

Enrollment

160

Registered

2022-02-18

Start date

2022-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection (COVID-19) Coronavirus infection (COVID-19)

Interventions

Arm highly bioavailable curcumin : curcuRougeTM (90mg/capsule), 4 capsules are given twice a day. (8 capsules/day, morning and evening) for 7 days. Arm placebo : 4 capsules are given twice a day, (8 c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Within 5 days after being diagnosed as COVID-19 by PCR test or antigen test (described in the guideline for medical treatment of COVID-19, 5.3 th edition (Ministry of Health, Labor and Welfare)). (2) Receiving no oxygen therapy and SpO2 is 96% or higher. (3) Body temperature is less than 37.5 degree Celsius. (4) Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1. (5) Age 20 years or older, both gender (6) Written informed consent was obtained.

Exclusion criteria

Exclusion criteria: (1) Patients taking antithrombotic drugs (anticoagulants, EPA preparations, prostacyclin preparations) (2) Patients with a history of cerebral hemorrhage (3) Patients receiving oxygen therapy at home or dialysis (4) Patients with end-staged cancer (5) Patients taking steroids on a regular basis (6) Regular users of healthy foods containing curcumin (7) Patients with a history of allergies to curcumin (8) Pregnant women and those who are breastfeeding or may become pregnant (9) Patients who are scheduled to recieve neutralizing antibody therapy or anti-virus drugs. (10) Those who are judged by the principal investigator or the research coordinator to be inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
Combination of the following events SpO2 progress to less than 96%, fever more than 37.5 degree Celsius, and death	—

Secondary

Measure	Time frame
Each of the following events SpO2 progress to less than 96%, fever more than 37.5 degree Celsius, and death Adverse events	—

Contacts

Public ContactKoji Hasegawa

National Hospital Organization Kyoto Medical Center

koj@kuhp.kyoto-u.ac.jp+81-75-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026